NEW APPROACH FOR INHIBITING REV FUNCTION AND HIV-1 PRODUCTION USING THE INFLUENZA-VIRUS NS1 PROTEIN

The Rev protein of HIV-1, which facilitates the nuclear export of HIV- 1 pre-mRNAs, has been a target for antiviral therapy. Here we describe a new strategy for inhibiting Rev function and HIV-1 replication, In contrast to previous approaches, we use a wild-type rather than a muta nt Rev protein and covalently link this Rev sequence to the NS1 protei n of influenza A virus, a protein that inhibits the nuclear export of mRNAs. The NS1 protein contains an RNA-binding domain mutation (RM), s o that the only functional RNA-binding domain in the chimeric protein (NS1RM-Rev) is in the Rev protein sequence. In the presence of the NS1 RM-Rev chimeric protein, HIV-1 pre-mRNAs were retained in, rather than exported from, the nucleus. In addition, this chimeric protein effect ively inhibited Rev function in trans in transfection experiments and effectively inhibited the production of HIV-1 in tissue culture cells transfected with an infectious molecular clone of HIV-1 DNA. The inhib itory activities of the NS1RM-Rev chimera were at least equivalent to those of the Rev M10 mutant protein, which has been considered to be t he prototype trans inhibitor of Rev function and is currently in phase I clinical trials for the treatment of AIDS patients. we discuss (i) the potential for increasing the inhibitory activity of NS1-Rev chimer as against HIV-I and (ii) the need for additional studies to evaluate these chimeras for the treatment of AIDS.